banner news

Singapore, January 31, 2020 – Credo Diagnostics Biomedical Pte. Ltd., a groundbreaking point-of-care rapid molecular diagnostic company, announced today they will attend the Medlab Middle East exhibition that will take place at the Dubai World Trade Centre from February 3 to February 6.


Credo Diagnostics Biomedical will be showcasing it product line of point-of-care molecular diagnostic solution including the VitaPCR platform and Influenza A&B assay, the new QubeMDx+ platform and assays, as well as the upcoming fastest auto-extractor in the world, the Purexon.


Credo Diagnostics Biomedical will be located at the booth #Z4.D29, where they will be meeting with individual practitioners, laboratory technicians, scholars, and potential business partners.



About Credo Diagnostics Biomedical Pte. Ltd.

Credo Diagnostics Biomedical develops, and manufactures innovative, cost-effective, and rapid Molecular Diagnostic solutions at the Point-of-Care (POC) in the areas of Animal Health, Human Health, and Human Wellness. By providing the right information, at the right time, and to the right people, we can improve the lives of billions of people and animals around the world.



We at Credo Diagnostics Biomedical pioneer accessible diagnostic platforms to improve the lives of those we love. We believe providing the right information to the right people at the right time leads to better outcomes.